Zacks Investment Research
02 Nov 2026, 17:41 UTC · 1h ago
Charles River's Q3 Earnings on Deck: What's in Store for the Stock?
Impact · against what's priced in
The upcoming earnings report for Charles River Laboratories is unlikely to provide a positive catalyst as the market has already factored in organic revenue declines and the impact of the Cell Solutions divestiture. The current estimates for revenue and EPS reflect a challenging academic and government funding environment.
- CRL−0.20
No priced-in read yet
- In context
The company faces a 4.8% projected year-over-year revenue decline and continued pressure in the RMS segment due to flat NIH budgets and lower demand for small models.
Read from the article alone
Top 2 movers · tap to explore
